Deals Of The Week: Allena/Althea, Almirall/Menarini, Bausch & Lomb/Ista
Executive Summary
Earn-outs are more frequent in biotech M&A deals these days, but private investors also are becoming more savvy in terms of tracking earn-outs and which ones are more likely than others to pay off.
You may also be interested in...
Vertex's Cystic Fibrosis Drug Kalydeco Given Green Light By EU's Scientific Advisory Panel
Vertex's cystic fibrosis product Kalydeco is one of five new molecular entities given a positive opinion by Europe's Committee for Medicinal Products for Human Use on May 25, which also included Almirall's novel COPD therapy aclidinium and Novo Nordisk's recombinant Factor XIII.
Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target
The diabetes drug maker has reportedly spurned a buyout offer at a 43% premium, driving up its share price – and perhaps discouraging it from pursuing the partnership it seeks.
Panel Pushes For “Pragmatic” Post-Marketing Study, Head-To-Head Comparison For Forest’s Aclidinium
FDA’s Pulmonary-Allergy Drugs Advisory Committee suggests including endpoints that will help determine the value added by the COPD drug. Forest Labs says it is ready to discuss post-marketing options with FDA.